公司概述
UnitedHealth Group Incorporated operates as a comprehensive healthcare enterprise serving both domestic and international markets through four distinct segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. The Optum Health segment specifically focuses on care delivery, care management, wellness initiatives, and consumer engagement, distinguishing it from the other segments within the broader portfolio. This entity functions within the Healthcare sector, specifically classified under the Healthcare Plans industry, positioning it as a key player in the management and financing of medical services. The company demonstrates massive scale with a market capitalization of $277.73B and an annual revenue of $447.57B, supported by a workforce of 390,000 employees. These valuation and revenue figures indicate that UnitedHealth Group holds a dominant position within the healthcare ecosystem, reflecting its substantial influence over the delivery and payment structures of medical services in the United States.
财务健康
The company reported a revenue of $447.57B over the trailing twelve months, generating a net income of $12.06B and an EBITDA of $21.62B during the same period. The significant disparity between the total revenue figure and the net income figure reveals a substantial cost structure, where operating expenses, including costs associated with the four segments, consume a large portion of top-line growth before reaching the bottom line. UnitedHealth Group maintains a free cash flow of $13.86B, which provides the organization with significant financial flexibility to fund capital expenditures, reduce debt, or pursue strategic acquisitions without relying on external financing. The margin profile shows a gross margin of 18.5%, an operating margin of 0.3%, and a profit margin of 2.7%, indicating that while the company generates substantial top-line volume, it faces intense competition and high operational costs that constrain profitability at the operating and net levels. Regarding liquidity and leverage, the company holds $28.12B in cash against $83.00B in total debt, resulting in a debt-to-equity ratio of 81.62, which suggests a highly leveraged balance sheet relative to its equity base. Despite the high debt load, the current ratio stands at 0.79, indicating that the company's current assets are insufficient to cover its current liabilities without relying on asset sales or external financing. Furthermore, the return on equity is 12.5% while the return on assets is 3.9%, highlighting that management is generating returns that are disproportionately weighted toward shareholders compared to the total asset base, a dynamic often influenced by the high leverage levels present.
估值评估
Valuation metrics for UnitedHealth Group show a trailing P/E ratio of 23.15 compared to a forward P/E of 15.22. This substantial difference between the trailing and forward multiples implies that the market expects a significant improvement in earnings trajectory in the coming years, as the forward multiple is considerably lower than the historical average. The price-to-book ratio is 2.95, which indicates that the market values the company at nearly three times its book value, suggesting a premium assigned to the company's intangible assets and future growth potential rather than its tangible net worth. Alternative valuation metrics include a price-to-sales ratio of 0.62 and an EV/EBITDA of 15.73, which provide context on how the company is valued relative to its sales revenue and earnings before interest, taxes, depreciation, and amortization. Price action over the last year has seen the stock trade between a 52-week high of $606.36 and a 52-week low of $234.60. Without the current specific share price provided in the data, the precise percentage distance from the high cannot be calculated, but the wide range underscores the significant volatility experienced within the trading period. The beta value is 0.41, which indicates that the stock's price volatility is less than half that of the broader market, suggesting it behaves as a defensive asset that moves less dramatically than the general equity index.
Growth & Income
The company experienced a revenue growth of 12.3% year-over-year, whereas earnings growth was -99.9% for the trailing twelve months. This divergence indicates that earnings are currently growing significantly slower than revenue, a trend often associated with one-time charges, accounting adjustments, or specific segment performance issues that depress the bottom line despite top-line expansion. As a dividend payer, UnitedHealth Group offers a dividend yield of 2.9% with a payout ratio of 66.0%. This payout ratio suggests that the company returns a majority of its earnings to shareholders, and its sustainability depends heavily on the resolution of the recent earnings decline to align cash flows with dividend obligations. The overall growth and income profile is characterized by robust top-line expansion that contrasts sharply with recent earnings volatility, while the dividend yield provides a steady income stream despite the temporary compression in profit margins.